Reference number : GC-2017-Q1-00234, amendment number : , agreement type : G, recipient legal name : Allingham, John (Queen’s University), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : Cancer metastasis involves the spread of cancer cells from one organ to another and is the_x000D_
cause of 90% of cancer-related deaths. Current therapies fail to block metastasis effectively,_x000D_
and our invention of novel actin-targeted ADCs will address this unmet need. Dynamic_x000D_
modifications of the actin cytoskeleton are essential for cancer cells to breakthrough tissue_x000D_
and blood vessel barriers during metastasis. Targeting this "actin addiction" is the goal of this_x000D_
project, which is built on our detailed knowledge of potent natural inhibitors of actin. Our_x000D_
multidisciplinary team has designed, synthesized and tested novel actin toxin analogs that_x000D_
block growth, motility and invasion of metastatic cancer cells in vitro. Currently, we are linking_x000D_
these to antibodies used in oncology, and will test these novel ADCs in preclinical mouse_x000D_
models of metastatic cancers relevant to each clinically used antibody. These studies will_x000D_
measure effects of our ADCs on tumour progression and metastasis., program purpose french : Cancer metastasis involves the spread of cancer cells from one organ to another and is the_x000D_
cause of 90% of cancer-related deaths. Current therapies fail to block metastasis effectively,_x000D_
and our invention of novel actin-targeted ADCs will address this unmet need. Dynamic_x000D_
modifications of the actin cytoskeleton are essential for cancer cells to breakthrough tissue_x000D_
and blood vessel barriers during metastasis. Targeting this "actin addiction" is the goal of this_x000D_
project, which is built on our detailed knowledge of potent natural inhibitors of actin. Our_x000D_
multidisciplinary team has designed, synthesized and tested novel actin toxin analogs that_x000D_
block growth, motility and invasion of metastatic cancer cells in vitro. Currently, we are linking_x000D_
these to antibodies used in oncology, and will test these novel ADCs in preclinical mouse_x000D_
models of metastatic cancers relevant to each clinically used antibody. These studies will_x000D_
measure effects of our ADCs on tumour progression and metastasis., agreement title english : Development of antibody-drug conjugates that use actin-targeting warheads, agreement title french : Development of antibody-drug conjugates that use actin-targeting warheads, agreement number : CHRPJ, agreement value : 248750.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada